PMID: 7372372Apr 15, 1980Paper

Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay

International Journal of Cancer. Journal International Du Cancer
K C WangA H Sehon

Abstract

Some parameters of the Winn assay for the detection of tumor-suppressing ("effector") and tumor-enhancing lymphoid cells were studied in BALB/c mice. Spleen cells of mice that were preimmunized with mitomycin-C-treated MOPC-104E plasmacytoma cells were inhibitory in this test system for both the MOPC-104E and the HOPC-I plasmacytomas, thus indicating cross-reactivity. Spleen cells taken from mice 6 days after the surgical removal of 15-day-old MOPC-104E tumors inhibited the growth of lethal doses of MOPC-104E cells in normal recipients, but no inhibition was observed 2 days after the removal of 18-day-old tumors. Spleen cells from mice bearing MOPC-104E for 13 days enhanced tumor growth. This enhancement was not influenced significantly by the wide dose range (from 10(5) to 3 x 10(7)) of MOPC-104E cells used to initiate tumors in the lymphoid cell donors, although tendency for stronger enhancing potential occurred after low tumor doses. When spleen cells from donors bearing MOPC-104E for 10 days were injected at the constant tumor-lymphocyte ratio of 1:30 with increasing numbers of tumor cells (from 5 x 10(5) to 2 x 10(6)), tumor inhibition occurred at the lowest dose only, while no significant effect was observed at higher tum...Continue Reading

References

Aug 15, 1975·International Journal of Cancer. Journal International Du Cancer·R B HerbermanD H Lavrin
Dec 15, 1977·International Journal of Cancer. Journal International Du Cancer·J H DeanL W Law
Jan 15, 1975·International Journal of Cancer. Journal International Du Cancer·S B HowellL W Law
Nov 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·M I GreeneB Benacerraf
Feb 1, 1979·International Journal of Cancer. Journal International Du Cancer·I Berczi, A H Sehon
Sep 1, 1977·British Journal of Cancer·L J PetersW H McBride
Jan 1, 1977·Immunological Communications·I Berczi, A H Sehon
Jan 1, 1975·Immunological Communications·S FujimotoA H Sehon
Jul 15, 1975·International Journal of Cancer. Journal International Du Cancer·P HerseyG W Milton
Oct 1, 1975·Journal of the National Cancer Institute·R B Herberman, R K Oldham
Jun 22, 1973·Science·I BercziA H Sehon
Jan 1, 1973·Advances in Cancer Research·R W Baldwin
Nov 1, 1974·European Journal of Immunology·A J TrevesI R Cohen
Jan 1, 1974·Advances in Immunology·K E Hellström, I Hellström
Jul 1, 1973·British Journal of Cancer·O Fakhri, J R Hobbs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.